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Summary
The frequent silencing of tumor suppressor genes by altered cytosine methylation and chromatin structural changes makes
this process an attractive target for epigenetic therapy. Here we show that zebularine, a stable DNA cytosine methylation
inhibitor, is preferentially incorporated into DNA and exhibits greater cell growth inhibition and gene expression in cancer
cell lines compared to normal fibroblasts. In addition, zebularine preferentially depleted DNA methyltransferase 1 (DNMT1)
and induced expression of cancer-related antigen genes in cancer cells relative to normal fibroblasts. Our results demon-
strate that zebularine can be selective toward cancer cells and may hold clinical promise as an anticancer therapy.
Introduction DNA (Bouchard and Momparler, 1983; Taylor et al., 1984). Once
incorporated into DNA, both compounds can form covalent
complexes with DNA methyltransferases (DNMTs), leading to aAbnormal hypermethylation of the promoters of numerous can-
cer-related or tumor suppressor genes important in cellular pro- depletion of active enzymes (Bouchard and Momparler, 1983;
Santi et al., 1983, 1984; Taylor et al., 1984). Clinically, theseliferation is commonly found in primary neoplasms and tumor
cell lines (Baylin et al., 2001; Baylin and Herman, 2000; Jones agents have already shown utility for the treatment of leukemia
and myelodysplastic syndromes (Lubbert, 2000). Nevertheless,and Baylin, 2002; Jones and Laird, 1999). Because epigenetic
processes are potentially reversible, pharmacologic inhibitors of these mechanism-based inhibitors of DNMTs have some draw-
backs. Both drugs are quite toxic in vitro and in vivo, and they areDNA methylation provide a conceptually attractive and rational
approach to reestablish the antiproliferative and other crucial unstable in aqueous solution, making them difficult to administer
both experimentally and clinically (Beisler, 1978).cellular functions that are abnormally silenced by hypermethy-
lation. We recently characterized zebularine as a novel mechanism-
based inhibitor of DNA methylation, exhibiting great stability inThe first described specific inhibitors of DNA methylation,
5-Azacytidine (5-Aza-CR) and its deoxy analog, 5-Aza-2-deoxy- acidic and neutral solutions and minimal toxicity both in vitro
and in vivo (Cheng et al., 2003). As a cytidine analog containingcytidine (5-Aza-CdR), were both originally synthesized as cancer
chemotherapeutic agents (Jones and Taylor, 1980; Sorm et a 2-(1H)-pyrimidinone ring, zebularine was initially developed
as a cytidine deaminase inhibitor, because it lacks the aminoal., 1964). Both are pyrimidine ring analogs of cytidine and 2-
deoxycytidine, respectively, but have nitrogen atoms in place group on C-4 of the pyrimidine ring (Kim et al., 1986; Laliberte
et al., 1992). Similar to 5-Aza-CR and 5-Aza-CdR, zebularineof the C-5 pyrimidine carbon atoms. 5-Aza-CR is primarily acti-
vated by uridine-cytidine kinase and can be incorporated into has been shown to form a tight, covalent complex with bacterial
methyltransferases in vitro (Hurd et al., 1999; Zhou et al., 2002).both RNA and DNA, whereas 5-Aza-CdR is activated by deoxy-
cytidine kinase and is only incorporated into newly synthesized However, a major concern with the usage of nucleoside analogs
S I G N I F I C A N C E
Demethylating agents have great potential clinical promise in reversing the hypermethylation evident in human cancers. However,
the use of these agents is often limited by their cytotoxicities and nonspecific effects on both normal and cancer cells, as well as
by their inabilities to permanently reverse methylation. Our study shows that a stable DNA cytosine DNA methylation inhibitor,
zebularine, preferentially targets cancer cells compared to normal fibroblasts, in terms of incorporation into DNA, reduction of DNA
methyltransferase levels, and induction of gene expression. Thus, zebularine is selective toward cancer cells and may represent a
candidate drug for epigenetic therapy.
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as inhibitors of DNA methylation is the potential for nonspecific
effects toward normal cells.
Zebularine can be administered to T24 cells in a continuous
fashion to effectively sustain demethylation of the p16 5 region
and other methylated loci (Cheng et al., 2004). The purpose of
this study was to compare the effects of continuous zebularine
treatment on normal fibroblasts and cancer cells. We studied
the incorporation of zebularine into DNA and its effects on the
growth, methylation, and DNMT protein levels in a panel of
four normal fibroblasts and seven cancer cell lines. Lastly, we
performed a gene expression microarray chip on four normal
fibroblasts and three cancer cells. We found that a larger number
of genes were activated in the cancer cells than in the normal
fibroblasts, and most of these genes that were activated be-
longed to a cluster of tumor antigen genes, including MAGE-,
GAGE-, and XAGE-type cancer-testis antigens. The augmen-
tation of tumor antigen genes by zebularine suggests that this
drug may have antitumor potential in combination with immuno-
therapy.
Results
Zebularine preferentially inhibits the growth
of cancer cells
A major concern for the clinical application of nucleoside ana-
logs is their nonspecific effects toward both normal and cancer
cells. Previously, we have demonstrated the growth suppression
of T24 bladder cancer cells after continuous treatment with
zebularine (Cheng et al., 2004). To further investigate the growth
inhibitory effects of continuous zebularine treatment, we ex-
tended our study to a panel of seven human cancer cell lines
including T24, HCT15, CFPAC-1, SW48, HT-29, PC3, and
CALU-1, as well as including four normal human fibroblast cell
lines (LD98, T-1, LD419, and CCD-1070Sk). Interestingly, con-
tinuous treatment with zebularine substantially retarded the
growth of all human cancer cell lines, but the growth of normal Figure 1. Effects of zebularine on growth suppression and methylation in
normal and cancer cellshuman fibroblasts was less affected (Figure 1A). We next exam-
A panel of normal fibroblasts (LD98, T-1, LD419, and CCD-1070Sk) and can-ined whether this growth inhibitory effect was associated with
cer cell lines (T24 bladder cancer, HCT15, SW48, and HT-29 colon cancer,upregulation of the mRNA for p21(WAF1) and/or p27(KIP1),
CFPAC-1 pancreatic cancer, PC3 prostate cancer, and CALU-1 lung can-which are inhibitors of cyclin-CDK complexes involved in G1 cer cells) were either untreated or treated in the presence of 104 M zebular-
and S phase progression (Gong et al., 2003; Gotz et al., 1996; ine continuously for 8 days.
Tam et al., 1994). Growth inhibition in cancer cells by zebularine A: The effects of zebularine on cell growth were analyzed in these cell lines
by comparing doubling times before and after drug treatment. The percentwas found to be associated with a 2- to 7-fold induction of the
increase represents the increase in doubling time of cells after treatmentp21 mRNA levels, whereas p27 mRNA levels remained relatively
as compared to the untreated control cells. Expression levels of p21 andunchanged (Figure 1A). Both p21 and p27 mRNA were unaf- p27 mRNAs were determined by RT-PCR analysis. GAPDH mRNA expression
fected by zebularine in all four normal fibroblasts. All of the levels were measured to control for relative cDNA input.
B: The effects of zebularine on p16 gene expression and methylation ofcancer cells were therefore more responsive than normal fibro-
various loci. The expression level of p16 mRNA was determined by RT-PCRblasts to the growth-suppressive effects of zebularine, and
analysis. The GAPDH mRNA expression levels were the same ones shownthese effects were seemingly p21-dependent.
above in A. Methylation status of the p16 5 region, M4-4, and D4Z4 was
quantitated by Ms-SNuPE analysis (as described in the Experimental Proce-
Effects of zebularine on p16 gene expression dures). Methylation percentage represents the average of three individual
CpG sites in each region as assayed from two independent experiments.and demethylation
To further evaluate the enhanced growth inhibition of cancer
cells by zebularine, we next analyzed the reexpression of the
p16 gene, which is known to be abnormally silenced by DNA
methylation levels of the 5 region of the p16 gene were de-methylation in all of these cancer cell lines. The p16 gene was
creased by zebularine treatment in the five cell lines that wereexpressed and was mostly unmethylated in the normal fibro-
inducible (Figure 1B). Interestingly, the p16 gene was eventuallyblasts, and the mRNA expression was largely unaffected by
activated in CALU-1 cells after 22 days of continuous treatmentzebularine treatment (Figure 1B). On the other hand, the p16
(data not shown), suggesting that these cells are more resistantgene was induced in T24, HCT15, CFPAC-1, SW48, and HT-
29, but not in PC3 or CALU-1 cancer cells (Figure 1B). The to the demethylating effects of zebularine. These results also
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suggest that the growth inhibitory effects of zebularine may be
partially due to the upregulation of p21 gene in all seven cancer
cell lines and/or the induction of p16 in T24, HCT15, CFPAC-1,
SW48, and HT-29 cells.
We then assayed the methylation levels of two other loci
that are known to be methylated in both normal and cancer cell
lines. M4-4 is a single copy sequence located in a CpG island
that was previously characterized in our laboratory (Cheng et
al., 2004), while D4Z4 is a subtelomeric repeat sequence (Kondo
et al., 2000). Both M4-4 and D4Z4 are highly methylated in all
cell lines, and our results show that measurable demethylation
was observed only in T24, HCT15, CFPAC-1, SW48, and, to a
lesser extent, HT-29 cells, and minimal changes were observed
in the methylation status in all normal fibroblasts, PC3, and
CALU-1 cancer cells (Figure 1B). Consistent with the finding for
the methylation of the p16 5 region, the methylation level of
these loci was mostly unaffected by zebularine in all normal
Figure 2. Effects of zebularine on DNMT protein levels in normal and cancerfibroblasts, as well as the two cancer cell lines that were refrac-
cellstory to the induction of the p16 gene by zebularine.
Western blot analysis of DNMT1, -3a, and -3b2/3 protein levels after continu-
ous zebularine treatment (104 M) for 8 days in a panel of (A) normal fibro-
Depletion of DNMT levels by zebularine blasts (LD98, T-1, LD419, and CCD-1070Sk) and (B) cancer cell lines (T24
The mechanism by which zebularine induces demethylation al- bladder cancer, HCT15, SW48, and HT-29 colon cancer, CFPAC-1 pancre-
atic cancer, PC3 prostate cancer, and CALU-1 lung cancer cells). Eithermost certainly requires the incorporation of the drug into the
DNMT3b2 or -3b3 represents the predominant isoform in that specific cellDNA and the formation of covalent complexes with DNMT(s) as
line. Cell lysates were obtained from treated and untreated control cellsis the case with both 5-Aza-CR and 5-Aza-CdR (Bouchard and (as described in the Experimental Procedures) and were analyzed by West-
Momparler, 1983; Hurd et al., 1999; Santi et al., 1984; Taylor ern blot analysis with specific antibodies for DNMT1, DNMT3a, and DNMT3b
proteins.et al., 1984; Zhou et al., 2002). Different assays have been
developed to track the levels of extractable DNMTs and individ-
ual DNMTs bound to genomic DNA using antibodies specific
for each DNMT (Liu et al., 2003; Velicescu et al., 2002). We
cytidine kinase activity, since this “salvage” enzyme is responsi-had previously shown the effects of continuous treatment with
ble for phosphorylating zebularine to the monophosphate level,zebularine on the protein levels of DNMTs in T24 bladder cancer
which is the first step for eventual incorporation into nucleiccells using Western blot analysis (Cheng et al., 2004). It was of
acids. The uridine/cytidine kinase activity levels in the cancerobvious interest to analyze the protein levels of DNMT1, -3a,
cell lines were generally (3- to 40-fold) higher than that in theand -3b in the normal and cancer cells before and after continu-
normal fibroblasts (Figure 3). The only exception was theous zebularine treatment. Zebularine treatment decreased the
CALU-1 cell line, which had low uridine/cytidine kinase activity.levels of extractable DNMT1 in all normal fibroblasts, as well
We next directly measured the level of radioactive zebularineas PC3 and CALU-1 cancer cells; however, the presence of
incorporated into the DNA in each cell line. Preliminary experi-residual bands on the blots suggested that methylation capacity
ments (data not shown) confirmed that incorporation was de-was not completely lost (Figures 2A and 2B). On the contrary,
pendent on cell division and showed that incorporation ofzebularine caused almost complete depletion of DNMT1 in T24,
2-[14C]-zebularine was almost completely inhibited by the pres-HCT-15, CFPAC-1, SW48, and HT-29 cancer cells (Figure 2B).
ence of a 1% level of nonradioactive cytidine, confirming thatThe levels of DNMT3a and -3b2/3 proteins in all cell lines were
the initial activation of the drug is probably dependent on uridine/less consistently affected. The mRNA levels of each DNMT, as
cytidine kinase. Our results showed a similar trend to the uridine/measured by semiquantitative RT-PCR, remained unchanged
cytidine kinase activity levels, in that cancer cells showed higherafter zebularine treatment (data not shown), suggesting that the
levels (2- to 50-fold) of incorporation than the normal fibroblasts.depletion of DNMT proteins was due to trapping of the enzymes
These results were generally consistent with the fact that zebu-to the zebularine-incorporated DNA rather than an inhibition of
larine had greater inhibitory effects and demethylating effectstranscription or cell proliferation. Cells that were refractory to
the demethylating effects of zebularine showed partial depletion on cancer cell lines than normal fibroblasts, except for PC3
and CALU-1 cells, which both have moderate levels of DNAof DNMT1, -3a, and -3b. For instance, PC3 and CALU-1, as
well as the normal fibroblasts, showed only partial depletion of incorporation, yet minimal effect on DNA methylation. These
latter results suggest that incorporation of the fraudulent baseDNMT1. These data suggest that a complete depletion of
DNMT1 is likely a critical requirement for demethylation and into DNA is not sufficient to inhibit DNA methylation in itself and
that there may be other factors that dictate the final outcome.gene induction to occur.
Cancer cells preferentially incorporate zebularine Zebularine substantially alters gene expression
in human cancer cellsinto DNA
The differential effects of the drug on cancer cells might be due We also wanted to investigate the effects of continuous zebular-
ine treatment on global gene expression profiles in normal andto preferential incorporation of zebularine into DNA. In our first
approach to this issue, we measured the levels of the uridine/ cancer cells. A high-density oligonucleotide gene expression
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Discussion
An important concern for the clinical application of DNA methyl-
ation inhibitors is whether they will nonselectively affect normal
as well as cancer cells. Here we have shown that zebularine
can preferentially target cancer cells compared to normal fibro-
blasts, in terms of incorporation into DNA, growth inhibition,
demethylation, and depletion of DNMTs. We are currently test-
ing the generality of these findings by testing the response of
normal epithelially derived cells to zebularine. While it is possible
that they will not react in the same way as fibroblasts, our earlier
studies using mice given daily doses of zebularine showed little
evidence of toxicity (Cheng et al., 2003). Zebularine may there-
fore be selective toward cancer cells and have potential as an
anticancer therapy.
Figure 3. Level of incorporation of 2-[14C]-zebularine into DNA and level of Although five of the seven cancer cells that were treated
uridine/cytidine kinase activity in normal and cancer cells with zebularine showed p16 induction, all of them showed an
Cells in logarithmic phase were plated onto 60 mm dishes and treated 24 upregulation of the p21 but not the p27 gene. These CDK inhibi-
hr later with 2-[14C]-zebularine to measure the level of incorporation. Twenty- tors are known to be differentially regulated (Gong et al., 2003;four hours after the treatment, the cultures were harvested, and the radio-
Ilyin et al., 2003), and DNA methylation is unlikely to play a roleactivity incorporated into DNA was determined. The incorporation results
are expressed as counts per minute per 10,000 cells (adjusted for population in the modulation of their expression, because both genes were
doubling) (black bars). The levels of uridine/cytidine kinase activity are mea- expressed even in the untreated cells. The negative effects of
sured (as described in the Experimental Procedures) and are expressed as zebularine on the growth of all five cells might therefore be due
pmol/min/mg of proteins (white bars). Results represent the average values
to an induction of p21 and/or the p16 gene. The p21 proteinof two or three separate experiments. Error bars represent the standard
can directly arrest DNA replication in response to DNA damagedeviation of three separate determinations.
by binding to proliferating cell nuclear antigen (PCNA) (Waga
et al., 1994). The increased p21 expression points to a novel
mechanism for zebularine in addition to its effects on DNA meth-
microarray analysis on four normal fibroblasts (LD98, LD419, ylation. Nevertheless, other mechanisms, such as the induction
T-1, and CCD-1070k) and three cancer cell lines (T24, CFPAC-1, of apoptosis, may play an important role in the growth regulation
and HCT15) showed that a common set of 12 genes were of the cancer cells treated by zebularine (Nieto et al., 2004).
upregulated by 2-fold after 8 days of continuous drug treat- The preferential effects of zebularine for cancer cells are
ment in all three cancer cell lines, but not in the normal fibro- probably due to differential metabolism compared to normal
blasts (Table 1A). Interestingly, eight of these (67%) belonged cells. The drug requires activation by phosphorylation before it
to a cluster of tumor antigens, which include MAGE-, GAGE-, can be incorporated into nucleic acids, and the conversion of
and XAGE-cancer-testis antigens (Table 1A). The level of in- the nucleoside to the monophosphate is the first step in this
duced expression varied from 2-fold for MAGEA1 to a maximum process, which is catalyzed by the uridine/cytidine kinase en-
of 315-fold for SPANXA1 in T24 cells. The microarrays did not zyme. Once phosphorylated, the 2-(1H)-pyrimidinone ring can
detect the upregulation of p16 or p21 that was found earlier be incorporated into RNA and into DNA after the reduction by
(Figure 1), possibly due to technical issues related to the fact ribonucleotide reductase of the ribose moiety to deoxyribose.
that multiple transcripts are present in the p16 gene, making it Our data support the idea that uridine/cytidine kinase may serve
difficult for the software to score the low signal intensities. We as a potential gateway enzyme that predetermines the amount
cannot, however, explain the discrepancy between the results of zebularine that eventually gets into the DNA and probably
obtained for p21 expression. However, we previously verified RNA. Since lower levels of this enzyme were present in the
that genes detected as being increased on microarrays were normal cells, we would indeed expect less zebularine incorpora-
also shown to be upregulated by RT-PCR (Liang et al., 2002). tion into both RNA and DNA of normal fibroblasts. This was
A total of 6 out of 13,300 genes were found to be downregu- strongly supported by the incorporation data. Nevertheless, the
lated in all three cancer cell lines by continuous zebularine treat- level of uridine/cytidine kinase activity does not correlate per-
ment (Table 1B). Similarly, only one gene out of 13,000 genes fectly with the level of radioactive zebularine incorporation into
examined was found to be upregulated or downregulated in the DNA, probably due to fact that other enzymes in this pathway
might alter the incorporation into the DNA.common in all four normal fibroblasts (Tables 1C and 1D). This
result supports the idea that zebularine is relatively nontoxic in The incorporation of the 2-(1H)-pyrimidinone ring into DNA
is almost certainly required for the depletion of DNMT1 and thethat only a small number of genes were globally affected by
zebularine. Our earlier work on the global effects of gene expres- inhibition of DNA methylation that we observed in five of the
seven cancer cells. A disparity between the lack of demethyl-sion by 5-Aza-CdR in both T24 and LD419 cell lines (Liang et
al., 2002), as well as others, has also shown that a cluster of ation and zebularine incorporation was observed in both
CALU-1 and PC3 cancer cells by day 8 of continuous zebularinetumor antigens was activated in cancer cells but not in normal
cells (Karpf et al., 2004). Altogether, our data suggest the poten- treatment. We do not have an explanation for this observation
at present; however, treatment of CALU-1 cells with continuoustial utilization of zebularine in the upregulation of these tumor
antigens, which constitute promising targets for immunotherapy zebularine eventually reactivated the p16 gene by day 22, which
suggests that there may be a different threshold for each cell(Gillespie and Coleman, 1999; Weber et al., 1994).
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Table 1. Genes altered after zebularine treatment of the normal fibroblast and cancer cell lines
FC
Fibroblasts Cancer cells
Probe ID Unigene Gene symbol Map location LD98 LD419 T1 CCD-1070Sk T24 Cf-Pac HCT15
A: Genes upregulated 2-fold in all cancer cell lines, but not in fibroblast cell lines, 8 days after continuous zebularine treatment
Cancer-related antigens
207325_x_at Hs.72879 MAGEA1 xq28 1.1 2.8 1.0 2.3 2.1 5.3 10.6
206218_at Hs.113824 MAGEB2 xp21.3 1.1 1.6 1.1 1.6 2.5 2.6 4.6
207663_x_at Hs.176661 GAGE3 xp11.4-p11.2 1.4 1.5 1.4 1.3 6.1 4.0 7.0
208155_x_at Hs.272484 GAGE6 xp11.4-p11.2 1.2 1.4 1.9 1.2 2.8 9.8 11.3
208235_x_at Hs.278606 GAGE7 xp11.2-p11.4 1.7 3.2 1.4 3.0 2.6 9.2 17.1
206640_x_at Hs.251677 GAGE7B xp11.4-p11.2 4.9 1.2 1.4 1.1 3.2 9.8 24.3
220057_at Hs.112208 XAGE1 xp11.23 1.4 1.3 1.2 1.1 7.5 7.5 48.5
220922_s_at Hs.334464 SPANXA1 xq27.1 1.1 1.1 1.1 1.1 315.2 445.7 13.9
Other
204351_at Hs.2962 S100P 4p16 1.7 1.6 1.4 4.0 11.3 6.1 6.5
201739_at Hs.296323 SGK 6q23 1.3 1.1 1.6 1.3 2.1 2.8 2.6
200924_s_at Hs.79748 SLC3A2 11q13 1.5 1.1 1.1 1.1 2.8 3.7 2.0
214358_at Hs.449863 ACACA 17q21 1.1 1.3 1.3 1.4 10.6 2.3 2.0
B: Genes downregulated 2-fold in all cancer cell lines, but not in fibroblast cell lines, 8 days after continuous zebularine treatment
203081_at Hs.99816 CTNNBIP1 1p36.22 1.1 1.2 1.1 1.1 2.3 2.6 2.5
205014_at Hs.1690 HBP17 4p16-p15 2.6 1.1 1.3 2.3 8.6 5.7 4.0
202769_at Hs.79069 CCNG2 4q21.21 1.3 1.1 1.1 2.1 3.2 2.0 2.3
203453_at Hs.2794 SCNN1A 12p13 1.2 1.9 1.0 1.4 2.0 2.5 3.7
213279_at Hs.348350 DHRS1 14q11.2 1.1 1.0 1.2 1.0 2.0 2.0 2.8
219562_at Hs.3797 RAB26 16p13.3 1.3 1.4 1.1 1.7 5.3 3.7 4.9
C: Genes upregulated 2-fold in all fibroblast cell lines, but not in cancer cell lines, 8 days after continuous zebularine treatment
204637_at Hs.119689 CGA 6q12-q21 4.3 2.1 2.8 5.7 1.3 1.7 1.5
D: Genes downregulated 2-fold in all fibroblast cell lines, but not in cancer cell lines, 8 days after continuous zebularine treatment
221019_s_at Hs.29423 COLEC12 18pter-p11.3 2.0 3.0 13.9 2.0 1.5 1.2 1.3
FC, fold change.
line in terms of the amount of zebularine incorporation required of polyribosomes, coacceptor function of tRNA, and marked
inhibition of protein synthesis (Li et al., 1970; Momparler etin order for demethylation and gene activation to occur. The
threshold levels might be quite variable between each cell line, al., 1976; Reichman and Penman, 1973). The incorporation of
zebularine into RNA could thereby also conceivably explain thesince other factors, such as the rate of DNA repair, rate of
zebularine mutation, rate of DNA synthesis, ploidy numbers, growth inhibitory properties of the drug in all cancer cell lines,
including CALU-1 and PC3 cells. Zebularine might therefore betrans-acting factors, and potentially others may influence these
cells. Nevertheless, the cancer cells in general showed a greater multifactorial in its effects, but the preferential activity in cancer
cells makes it an exciting drug.level of incorporation of zebularine, which is consistent with the
growth inhibitory and demethylating effects observed in most The differential depletion of DNMTs by zebularine in the
normal and cancer cell lines is quite interesting. The levels ofof these cells.
The growth inhibitory effects of zebularine appeared to cor- DNMT1, DNMT3a, and DNMT3b2/3 were less affected in normal
fibroblasts after zebularine treatment, consistent with the obser-relate well with the level of zebularine incorporation into the
DNA. The normal cells had low zebularine incorporation and vation that less zebularine is incorporated into their DNA. The
cancer cells that responded to zebularine in terms of demethyl-exhibited minimal yet measurable effects on growth inhibition,
while the cancer cells had high levels of zebularine incorporation ation showed a complete depletion of DNMT1 and partial deple-
tion of DNMT3a and DNMT3b2/3. We had previously shownand exhibited greater growth inhibition. This suggests that the
growth inhibition seen in cancer cells but not in normal cells that zebularine preferentially depletes DNMT1 over the other
DNMTs in T24 cells (Cheng et al., 2004), implicating a moremay have resulted directly from the incorporation of the drug
into the DNA and the effects thereafter. Nonetheless, one cannot specific and higher affinity of this drug for DNMT1. We have also
previously shown that both 5-Aza-CdR and zebularine displayrule out the possibility that the growth-inhibitory effects may
also be exerted through their incorporation into RNA, which is differential depletion of DNMTs in T24 cells using Western blot
analysis (Cheng et al., 2004; Velicescu et al., 2002). The com-likely, since preliminary experiments have shown that the 2-(1H)-
pyrimidinone ring can be found in the RNA of treated T24 cells plete depletion of DNMT1 appeared to correlate with the de-
methylation of various loci in these cell lines, suggesting thatat levels ten times greater than the incorporation into the DNA
(T. Ben-Kasus et al., 2004, Proc. AACR, abstract). The incorpo- DNMT1 depletion may be an important indicator of the demeth-
ylating ability of zebularine.ration of 5-Aza-CR into RNA is known to produce disassembly
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SW48, HT-29, LD419, LD98, and T-1 cells were cultured in McCoy’s 5AThe reason for the apparent specificity of the 2-(1H)-pyrimi-
medium supplemented with 10% heat-inactivated fetal calf serum (FCS),dinone ring for the DNMT1 enzyme is unexpected, since all
100 units/ml penicillin, and 100 g/ml streptomycin (Gibco/Life Technolo-known cytosine-5 DNMTs appear to utilize the same mechanism
gies, Inc., Palo Alto, CA). HCT15 was cultured in RPMI 1640 medium supple-
of action (Cheng and Roberts, 2001). Perhaps zebularine exhib- mented with 10% FCS, penicillin/streptomycin, and 1 sodium pyruvate
its a greater enzymatic binding affinity for DNMT1 than for the (Gibco/Life Technologies, Inc.). CFPAC-1 was cultured in IMDM medium
other DNMTs. However, this is still unclear and needs to be supplemented with 10% FCS, penicillin/streptomycin, and 1 glutamine
(Gibco/Life Technologies, Inc.). CALU-1 was cultured in McCoy’s 5A mediumclarified. Nevertheless, it was recently shown that DNMT3b3
supplemented with 10% FCS, penicillin/streptomycin, and 1 glutamine.isoform has a reduced catalytic activity (Okano et al., 1999;
PC3 was cultured in RPMI 1640 medium supplemented with 5% FCS andSoejima et al., 2003), which might compromise its ability to
penicillin/streptomycin. CCD-1070Sk was cultured in MEM medium supple-
complex with zebularine, thereby explaining the partial depletion mented with 10% FCS, penicillin/streptomycin, 1 sodium pyruvate (Gibco/
of this enzyme by the drug. In addition, the partial depletion of Life Technologies, Inc.), and 1 MEM nonessential amino acids (Gibco/Life
DNMT3a by zebularine could potentially be due to the fact Technologies, Inc.). All cultures were grown in a humidified incubator at
37C in 5% CO2.that DNMT3a protein is expressed throughout the cell cycle, as
opposed to DNMT1 and DNMT3b, which are cell cycle regulated
Drug treatments(Robertson et al., 2000), and the depletion of DNMT3a can
All normal and cancer cell lines were plated (3  105 cells/100 mm dish)therefore only occur during the S phase, in which the 2-(1H)-
and treated 24 hr later with 104 M zebularine continuously for 8 days. The
pyrimidinone ring is incorporated into the DNA. medium was changed every 3 days thereafter along with fresh zebularine.
Our microarray data suggest that a combinatorial approach DNA, RNA, and protein lysates were harvested at the end of the treatment
for the treatment of human cancers could involve the use of period for methylation, RT-PCR, and Western blot analyses, respectively.
demethylating agents to augment the presentation of specific
Nucleic acid isolationcell surface antigens, which could then be targeted by immuno-
RNA was collected and extracted from cultured cells using the RNeasytherapy. Indeed, early studies by Frost et al. (1984) showed that
Protect Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s
5-Aza-CR could induce the formation of strongly immunogenic recommended protocol. DNA was collected as previously described (Gonza-
variants of mouse cells, providing support for this concept (Frost lez-Zulueta et al., 1995).
et al., 1984). The activation of cancer-related or tumor antigens
of the MAGE family has been observed in a number of human RT-PCR analysis
Total RNA (5 g) extracted from cultured cells was reverse transcribedcancers, and this was shown to correlate with genomic DNA
using MMLV reverse transcriptase (Invitrogen, Carlsbad, CA) and randomhypomethylation (De Smet et al., 1996). Based on these obser-
hexamers (Amersham-Pharmacia, Piscataway, NJ) in a total volume of 25vations, therapeutic strategies have been recently developed
l. The reverse transcription (RT) was performed as previously described
that strive to direct cellular immunity toward tumors that express (Gonzalez-Zulueta et al., 1995). cDNA was amplified with primers specific
MAGE antigens (Gillespie and Coleman, 1999). A caveat of this for either p16, p21, p27, or glyceraldehyde-3-phosphate dehydrogenase
strategy is that the majority of human tumors do not express (GAPDH). The RT-PCR conditions were as follows: for p16, 94C for 3 min,
28–30 cycles of 94C for 1 min, 56C for 30 s, 72C for 40 s, and a finalMAGE antigens; however, treatment of tumor cells with 5-Aza-
extension step at 72C for 5 min; for p21, 94C for 3 min, 18–23 cycles ofCdR induces their expression (Liang et al., 2002; Weber et al.,
94C for 1 min, 57C for 1 min, 72C for 1 min, and a final extension step1994). Our findings show that MAGE genes and other cancer-
at 72C for 5 min; for p27, the conditions were exactly the same as p21,
testis antigens represent a significant proportion of the genes except 26–28 cycles were used; for GAPDH, 94C for 1 min, 19 cycles of
upregulated by zebularine, and this appears to be specific to 94C for 1 min, 58C for 30 s, 72C for 45 s, and a final extension step at
cancer but not normal fibroblasts. Our microarray data also 72C for 2 min. The primer sequences are as follows: p16 sense, 5-AGC
CTT CGG CTG ACT GGC TGG-3; p16 antisense, 5-CTG CCC ATC ATCshow that only a small number of genes are downregulated in all
ATG ACC TGG A-3; p21 sense, 5-AGG GTG ACT TCG CCT GGG AGC-3;three cancer cells or all four normal fibroblasts after continuous
p21 antisense, 5-CAC ACA AAC TGA GAC TAA GGC AGA AGA TGT-3;zebularine treatment. These downregulated genes may be di-
p27 sense, 5-GCG CCT TTA ATT GGG GCT CCG GCT AA-3; p27 antisense,rectly affected by the drug itself or due to the indirect induction
5-GCT ACA TCC AAC GCT TTT AGA GGC AGA TCA-3; GAPDH sense,
of negative regulatory factors, as was postulated for 5-Aza-CdR 5-CAG CCG AGC CAC ATC GCT CAG ACA-3; and GAPDH antisense,
(Liang et al., 2002). Nevertheless, none of the downregulated 5-TGA GGC TGT TGT CAT ACT TCT C-3. RT-PCR amplification reactions
genes belonged to the group of cancer-specific antigens. The of each of the expressed genes were performed with 200 ng cDNA, 10%
dimethylsulfoxide (DMSO), 100 M dNTPs, Taq DNA polymerase (Sigma),combination regimen of zebularine followed by immunotherapy
and 1 M primers. The RT-PCR conditions, primers, and sequences forin the treatment of various human cancers will be the focus of
DNMT1, -3a, and -3b were performed as previously described (Robertsonfuture studies. In addition to its stability, minimal toxicity, and
et al., 1999). All reactions were analyzed in the linear range of amplification.
ability to sustain demethylation through continuous administra- PCR products were resolved on 2% agarose gels.
tion, zebularine is also relatively selective toward cancer cells
and thus represents a promising candidate for epigenetic Oligonucleotide array analysis
cRNA preparationtherapy.
Total RNA (10 g) was used as starting material for the cDNA preparation.
The first and second strand cDNA synthesis was performed using the Super-Experimental procedures
Script II System (Invitrogen Corp., Carlsbad, CA) according to the manufac-
turer’s instructions, except using an oligo-dT primer containing a T7 RNACell lines
T24 (bladder transitional carcinoma cells), HCT15, SW48, and HT-29 (colon polymerase promoter site. Labeled cRNA was prepared using the BioArray
High Yield RNA Transcript Labeling Kit (Enzo Life Sciences, Inc., Farming-carcinoma cells), CFPAC-1 (pancreatic carcinoma cells), CALU-1 (lung carci-
noma cells), and CCD-1070Sk (human normal fibroblasts) were obtained dale, NY). Biotin-labeled CTP and UTP (Enzo) were used in the reaction,
together with unlabeled triphosphates. Following the in vitro transcriptionfrom the American Type Culture Collection (Rockville, MD). PC3 (prostate
carcinoma) cells were kindly provided by Dr. Gerry Coetzee. LD419, LD98, reaction, the unincorporated nucleotides were removed using RNeasy col-
umns (Qiagen).and T-1 (human normal fibroblasts) were established in our laboratory. T24,
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Array hybridization and scanning and 72C for 20 s. The D4Z4 SNuPE primers are as follows: 5-TGA GGG
Fifteen micrograms of cRNA was fragmented at 94C for 35 min in a buffer TTG GGT TTA TAG T-3, 5-GTG GTT TAG GGA GTG GG-3, 5-TAT ATT
containing 40 mM Tris-acetate (pH 8.1), 100 mM potassium acetate, 30 mM TTT AGG TTT AGT TTT GTA A-3, 5-GAA AGG TTG GTT ATG T-3. The
magnesium acetate. Prior to hybridization, the fragmented cRNA in a 6 M4-4 SNuPE primers are as follows: 5-GGG TTT AGA TTA GGT TTT TT-3,
SSPE-T hybridization buffer (1 M NaCl, 10 mM Tris [pH 7.6], 0.005% Triton) 5-GTA ATA AGG ATT ATT TGA ATA G-3, 5-TAA TAA TGT GGA TTT GTT
was heated to 95C for 5 min and subsequently to 45C for 5 min before TAA ATT-3.
loading onto the Affymetrix HG_U133A probe array cartridge. The probe
array was then incubated for 16 hr at 45C at constant rotation (60 rpm). Radioactive incorporation assay
The washing and staining procedure was performed in the Affymetrix Fluidics All cell lines were plated (2  105 cells/60 mm dish) and treated 24 hr later
Station. The probe array was exposed to ten washes in 6 SSPE-T at 25C, with 0.75 Ci/ml 2-[14C]-zebularine for 24 hr. A separate dish of untreated
followed by four washes in 0.5 SSPE-T at 50C. The biotinylated cRNA cells was used for each cell line to determine the total number of cells per
was stained with a streptavidin-phycoerythrin conjugate (final concentration dish at the end of 24 hr treatment with a Z1 Coulter Particle Counter (Beck-
of 2 mg/ml; Molecular Probes, Eugene, OR) in 6 SSPE-T for 30 min at 25C, man Coulter Corporation, Hialeah, FL). Cells were washed three times with
followed by ten washes in 6SSPE-T at 25C. An antibody amplification step PBS, trypsinized, suspended in 450 l of water, lysed with 0.3 M KOH, and
was followed using normal goat IgG as blocking reagent (final concentration then incubated at 37C for 18 hr to hydrolyze RNA. Protein and DNA were
of 0.1 mg/ml; Sigma) and biotinylated anti-streptavidin goat antibody (final precipitated with 90% trichloroacetic acid (TCA) on ice for 5 min, and the
concentration of 3 mg/ml; Vector Laboratories, Burlingame, CA). This was DNA pellet was thoroughly washed with 5% TCA and hydrolyzed in 100 l
followed by a staining step with a streptavidin-phycoerythrin conjugate (final of 5% TCA for 30 min. The samples were centrifuged, and radioactivity in
concentration of 2 mg/ml; Molecular Probes) in 6 SSPE-T for 30 min at 50 l of supernatant was counted in 10 ml of scintillation fluid (Research
25C and 10 washes in 6 SSPE-T at 25C. The probe arrays were scanned Products International Corp., Mt. Prospect, IL) in a Packard Tri-Carb 1600
at 560 nm using a confocal laser-scanning microscope (Hewlett Packard TR Liquid Scintillation Spectrometer (Downers Grove, IL).
GeneArray Scanner G2500A; Affymetrix, Inc., Santa Clara, CA). The readings
from the quantitative scanning were analyzed by the Affymetrix Gene Expres- Uridine/cytidine kinase activity
sion Analysis Software. In our analysis, genes that were induced or The uridine/cytidine kinase activity in normal fibroblasts and cancer cells
reduced3-fold after drug treatment were categorized into different groups. was measured using assays modified as described by Luccioni et al. (1994).
Western blot analysis of DNMT protein levels Determination of cell doubling times
Cells were lysed by the addition of radioimmunoprecipitation (RIPA) buffer All cultured cells (3  105 cells/100 mm dish) were plated and treated with
(PBS, 0.1% SDS, 0.5% nonidet P-40, and 0.5% sodium deoxycholate), and 104 M zebularine 24 hr later and continuously for 8 days, with fresh zebular-
protein extracts were prepared as previously described (Velicescu et al., ine and media changes every 3 days. The cell number/dish was counted
2002). Approximately 60 g total protein extract was electrophoresed and with a Z1 Coulter Particle Counter (Beckman Coulter Corporation, Hialeah,
transferred to PVDF membranes overnight at 4C as previously described FL) every 2 to 3 days. Untreated cells were analyzed under similar conditions
(Velicescu et al., 2002). The membranes were hybridized with antibodies as a control. The average cell number from two plates was determined, and
against human DNMT1 (1:1000 dilution; New England Biolabs, Beverly, MA), the mean cell numbers were plotted to define the cell population doubling
human DNMT3b (T-16; 1:500 dilution; Santa Cruz Biotechnology, Santa times. Initial drug treatment was started 24 hr after seeding.
Cruz, CA), and proliferating cell nuclear antigen (PCNA) (1:4000 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA) in Tris-buffered saline-Tween Acknowledgments
(TBS-T) buffer (0.1 M Tris, 1.5 M NaCl, and 1% Tween 20) with 5% nonfat
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times with TBS-T buffer at room temperature and incubated with secondary
antibodies as follows: anti-mouse-IgG-HRP (1:3000 dilution for PCNA; Santa
Cruz), anti-rabbit-IgG-HRP (1:2000 dilution for DNMT1; Santa Cruz), anti-
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